#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Non-small cell lung cancer metastatic Dermatitis atopic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal adenocarcinoma Cervix carcinoma Synovitis Deafness Hypochromic anaemia Central nervous system neoplasm Oesophageal squamous cell carcinoma stage III Oesophageal carcinoma Enteritis Synovial sarcoma Infective uveitis Ornithine transcarbamoylase deficiency Chronic inflammatory demyelinating polyradiculoneuropathy Porphyria non-acute Neurodevelopmental disorder More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma – Treatment Marginal zone lymphoma – Treatment Hereditary motor and sensory neuropathy – Trials in Disease Congenital generalised lipodystrophy – Basic Information Ehlers-Danlos syndrome Congenital nephrogenic diabetes insipidus – Treatment Familial haemophagocytic lymphohistiocytosis – Basic Information IgA nephropathy – Treatment Aicardi-Goutieres syndrome – Life with Disease Small intestine leiomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cevostamab Protrans Gentamicin VGA039 Blu-263 Phosphate Keto-Isoleucine Calcium MAPLIRPACEPT Triamcinolone Hexacetonide RPTR-1-201 Meropenem Anhydrous Degarelix Acetate Ion440 Betula Verrucosa Pollen HSP-CAR19M Paltusotine Rct2100 Piromelatine Sparsentan TORASEMIDE Sitravatinib Malate More therapies…

    Learn about Your Condition

    Small cell lung cancer Caesarean section Pulmonary embolism Porphyria non-acute Meningococcal infection Carotid artery stenosis Biliary neoplasm Normal pressure hydrocephalus Malignant peritoneal neoplasm Angiosarcoma recurrent Cartilage injury Lichenoid keratosis Measles Anal incontinence Neonatal hyperglycaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Golexanolone for Patients with Primary Biliary Cholangitis Experiencing Fatigue and Cognitive Dysfunction

    Not recruiting

    1 1
    Investigated Diseases:
    • Primary biliary cholangitis
    Investigated Drugs:
    • Golexanolone
    Germany Greece Hungary Italy Spain

  • Study of Loncastuximab Tesirine for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma After CAR T-Cell Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    Investigated Drugs:
    • Loncastuximab Tesirine
    Italy

  • Study on the Safety of Avelumab for Patients with Solid Tumors Continuing Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Avelumab
    Bulgaria France Hungary Italy Poland Romania +1

  • Study on Tulisokibart for Treating Moderate to Severe Crohn’s Disease in Adults

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Tucidinostat
    • Nivolumab
    Belgium Czechia France Germany Italy Spain

  • Study of Durvalumab, Carboplatin and Etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    Investigated Drugs:
    • Carboplatin
    • Durvalumab
    • Etoposide
    Italy

  • Study on Cabozantinib for Patients with Liver Cancer Not Responding to Previous Immune Treatments

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Cabozantinib
    Italy

  • Study on Guselkumab for Healing in Crohn’s Disease Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    Belgium Czechia France Germany Italy Poland +2

  • Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Durvalumab
    Bulgaria France Hungary Italy The Netherlands Poland +2

  • Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia Denmark +10
Previous Page
1 … 66 67 68 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!